JO3262B1 - توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان - Google Patents

توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان

Info

Publication number
JO3262B1
JO3262B1 JOP/2010/0108A JOP20100108A JO3262B1 JO 3262 B1 JO3262 B1 JO 3262B1 JO P20100108 A JOP20100108 A JO P20100108A JO 3262 B1 JO3262 B1 JO 3262B1
Authority
JO
Jordan
Prior art keywords
decitabine
combination
cancer
deamiase
cytidine
Prior art date
Application number
JOP/2010/0108A
Other languages
English (en)
Inventor
Duvall Bridget
Hamiltion Gregory
Ferraris Dana
Belyakov Sergei
Vaal Mark
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of JO3262B1 publication Critical patent/JO3262B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بطرق لعلاج السرطان تشتمل على اعطاء ديسيتابين بالاشتراك مع مركبات تعمل على تثبيط نزع مجموعة الأمين للانزيم المسئول عن تثبيط ديسيتابين.
JOP/2010/0108A 2009-04-06 2010-04-06 توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان JO3262B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16711909P 2009-04-06 2009-04-06

Publications (1)

Publication Number Publication Date
JO3262B1 true JO3262B1 (ar) 2018-09-16

Family

ID=42357480

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0108A JO3262B1 (ar) 2009-04-06 2010-04-06 توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان

Country Status (11)

Country Link
US (1) US8329666B2 (ar)
EP (1) EP2416780B1 (ar)
JP (1) JP5730854B2 (ar)
AR (1) AR076263A1 (ar)
AU (1) AU2010234641B2 (ar)
CA (1) CA2757744C (ar)
ES (1) ES2628580T3 (ar)
JO (1) JO3262B1 (ar)
TW (1) TWI503121B (ar)
UY (1) UY32546A (ar)
WO (1) WO2010118010A1 (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2870937B2 (ja) 1990-02-26 1999-03-17 凸版印刷株式会社 金属蒸着フィルムの製造方法
JO2778B1 (ar) * 2007-10-16 2014-03-15 ايساي انك مركبات وتركيبات وطرق معينة
EP2416781B1 (en) * 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
CA2757743C (en) * 2009-04-06 2017-10-10 Eisai Inc. (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3) diazepin-2-0ne derivatives for treating cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
DK3383406T3 (da) 2015-12-03 2022-01-10 Epidestiny Inc Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin og anvendelser deraf
CA3045228C (en) 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
US11224610B2 (en) 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
DK3946322T3 (da) 2019-03-29 2023-11-27 Novocure Gmbh Fremgangsmåder til genoprettelse af sensitivitet over for ttfields i ttfields-resistente kræftceller med ptger3-inhibitorer
CA3236051A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4275057A (en) * 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1985001871A1 (en) 1983-10-26 1985-05-09 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
EP0184365B1 (en) * 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
AU664948B2 (en) 1993-02-23 1995-12-07 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
WO1994026761A1 (en) 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
EP1156827B1 (en) 1999-03-01 2006-09-20 Halogenetics, Inc. USE OF COMPOSITIONS COMPRISING CldC AS RADIOSENSITIZERS IN THE TREATMENT OF NEOPLASTIC DISEASES
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
DE60144573D1 (de) 2000-11-29 2011-06-16 Mitsui Chemicals Inc Verfahren und Zwischenprodukte bei der Synthese von L-Thymidin
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
EP1387850A2 (en) 2001-05-18 2004-02-11 Rakesh Kumar Antiviral nucleosides
US7772197B2 (en) 2002-09-24 2010-08-10 1,3,5-Triazines for Treatment of Viral Diseases 1,3,5-triazines for treatment of viral diseases
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
WO2006015346A1 (en) 2004-07-30 2006-02-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
EP1819718A1 (en) 2004-12-08 2007-08-22 Sicor Inc. Difluoronucleosides and process for preparation thereof
WO2008085611A2 (en) 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (ar) 2007-10-16 2014-03-15 ايساي انك مركبات وتركيبات وطرق معينة
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
EP2416781B1 (en) 2009-04-06 2017-03-08 Otsuka Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
CA2757743C (en) * 2009-04-06 2017-10-10 Eisai Inc. (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3) diazepin-2-0ne derivatives for treating cancer

Also Published As

Publication number Publication date
EP2416780A1 (en) 2012-02-15
ES2628580T3 (es) 2017-08-03
CA2757744A1 (en) 2010-10-14
WO2010118010A1 (en) 2010-10-14
AU2010234641A1 (en) 2011-11-10
JP2012522841A (ja) 2012-09-27
UY32546A (es) 2010-10-29
AR076263A1 (es) 2011-06-01
TW201102072A (en) 2011-01-16
AU2010234641B2 (en) 2016-04-21
TWI503121B (zh) 2015-10-11
US20100279967A1 (en) 2010-11-04
CA2757744C (en) 2018-02-13
EP2416780B1 (en) 2017-03-08
JP5730854B2 (ja) 2015-06-10
US8329666B2 (en) 2012-12-11

Similar Documents

Publication Publication Date Title
JO3262B1 (ar) توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان
MY191825A (en) Therapeutic compounds and compositions
EP2214495A4 (en) NATURALLY PHOTODYNAMIC ACTIVE SUBSTANCES AND ITS USE
TN2010000209A1 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
MX2009010066A (es) Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.
MY160041A (en) Compositions and methods for treating parasitic infections
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
MY161237A (en) Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer
NI201200090A (es) Composiciones para tratar náusea y vómito centralmente mediados
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
MX2010006991A (es) Tratamientos de cancer terapeuticos.
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
GB0920703D0 (en) Compositions containing satiogens and methods of use
TN2010000208A1 (en) Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
MY150650A (en) Pyrrolopyrimidine compounds and their uses
TW200612918A (en) Lonidamine analogs
MX2012004741A (es) Apremilast para el tratamiento de sarcoidosis.
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
TN2011000482A1 (en) Organic compounds and their uses
TNSN08400A1 (en) Organic compounds and their uses
PH12014501639B1 (en) Pharmaceutical compositions and methods
IL207310A0 (en) Vaccine compositions
MX2012006629A (es) Microorganismos probioticos como agentes activos contra cambios en microrelieve de la piel.